Cargando…
Anti interferon-gamma (IFNγ) monoclonal antibody treatment in a patient carrying an NLRC4 mutation and severe hemophagocytic lymphohistiocytosis
Autores principales: | Bracaglia, C, Gatto, A, Pardeo, M, Lapeyre, G, Ferlin, W, Nelson, R, de Min, C, De Benedetti, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597052/ http://dx.doi.org/10.1186/1546-0096-13-S1-O68 |
Ejemplares similares
-
Monocytes From Patients With Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis Are Hyperresponsive to Interferon Gamma
por: Pascarella, Antonia, et al.
Publicado: (2021) -
The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis
por: Prencipe, Giusi, et al.
Publicado: (2019) -
Use of a mouse model to identify a blood biomarker for IFNγ activity in pediatric secondary hemophagocytic lymphohistiocytosis
por: Buatois, Vanessa, et al.
Publicado: (2017) -
High levels of interferon-gamma (IFNγ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNγ production in MAS
por: Bracaglia, C, et al.
Publicado: (2015) -
Involvement of the IFN-gamma pathway in a patient with candle syndrome carrying a novel variant of PSMB8 gene
por: Insalaco, Antonella, et al.
Publicado: (2014)